Cara Therapeutics Inc
NASDAQ:TVRD
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Cara Therapeutics Inc
NASDAQ:CARA
|
83.4m USD |
-84%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
734.6B USD |
14%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-2%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
371.6B USD |
12%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
26%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
215.9B CHF |
9%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
165.9B GBP |
7%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
182.1B CHF |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
199.8B USD |
16%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-51%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
120.1B EUR |
10%
|
Cara Therapeutics Inc
Glance View
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Cara Therapeutics Inc's most recent financial statements, the company has ROA of -83.5%.
You don't have any saved screeners yet